Consensus Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 01:19:32 2025-01-23 pm EST			5-day change	1st Jan Change
275.60 ^USD	+0.79%		+2.25%	+5.70%

Jan. 17	Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	MT
Jan. 17	Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	MT

Evolution of the Average Target: Amgen Inc.

Evolution of the Target Price: Amgen Inc.

Changes in Analyst Recommendations: Amgen Inc.

8814888d0fdacbaa30c95ec6633a82.vQDdGtFsElWFqb-l-LQquNlXS0c50f0tXqfKHhFTnmA.yUeWV6gNZyX33t7xms5Q7axgJCF8lKIeE5SYSnph0wzzb49ynVt9IN2cjw~6b3bb2f7d3a78aaa7df9e84f8aeaf002

Analysts' recommendations: Amgen Inc.

Wells Fargo Cuts Price Target on Amgen to $280 From $335, Maintains Equalweight Rating	Jan. 10	MT
Goldman Sachs Adjusts Price Target on Amgen to $370 From $375, Maintains Buy Rating	Jan. 08	MT
Truist Lowers Price Target on Amgen to $298 From $333, Keeps Hold Rating	Jan. 08	MT
RBC Trims Price Target on Amgen to $324 From $330, Keeps Outperform Rating	Jan. 07	MT
Jefferies Adjusts Amgen Price Target to $350 From $380, Maintains Buy Rating	Dec. 19	MT
UBS Cuts Price Target on Amgen to $280 From $326, Maintains Neutral Rating	Dec. 17	MT
Deutsche Bank Lowers Amgen Price Target to $285 From $305, Maintains Hold Rating	Dec. 02	MT
Leerink Partners Adjusts Price Target on Amgen to $305 From $352, Maintains Market Perform Rating	Nov. 27	MT
Redburn Atlantic Adjusts Price Target on Amgen to $195 From $200, Maintains Sell Rating	Nov. 27	MT
Deutsche Bank Adjusts Price Target on Amgen to $285 From $305, Maintains Hold Rating	Nov. 27	MT
RBC Adjusts Price Target on Amgen to $330 From $360, Maintains Outperform Rating	Nov. 27	MT
Citigroup Adjusts Price Target on Amgen to $310 From $335, Neutral Rating Maintained	Nov. 26	MT
RBC Cuts Price Target on Amgen to $360 From $362, Maintains Outperform Rating	Nov. 25	MT
HSBC Adjusts Price Target on Amgen to $385 From $369	Nov. 13	MT
UBS Adjusts Price Target on Amgen to $326 From $335, Maintains Neutral Rating	24-10-31	MT
Goldman Sachs Adjusts Price Target on Amgen to $375 From $369, Maintains Buy Rating	24-10-31	MT
Morgan Stanley Raises Price Target on Amgen to $322 From $319, Keeps Equalweight Rating	24-10-31	MT
TD Cowen Adjusts Price Target on Amgen to $383 From $381	24-10-21	MT
TD Cowen Adjusts Amgen Price Target to $383 From $381	24-10-21	MT
Truist Downgrades Amgen to Hold From Buy, Raises Price Target to $333 From $320	24-10-14	MT
Morgan Stanley Adjusts Price Target on Amgen to $319 From $316	24-10-11	MT
JPMorgan Adjusts Price Target on Amgen to $300 From $290, Maintains Neutral Rating	24-10-09	MT
Goldman Sachs Adjusts Price Target on Amgen to $369 From $370	24-10-04	MT
Barclays Adjusts Price Target on Amgen to $315 From $300, Maintains Equalweight Rating	24-10-04	MT
Redburn Atlantic Adjusts Amgen Price Target to $200 From $180, Maintains Sell Rating	24-09-19	MT

More recommendations

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analyst Opinion	4m Revision of opinion	Divergence of analysts' opinions	Divergence of Target Price	Ecart obj. / dr
	AMGEN INC.					+16.02%
	ELI LILLY AND COMPANY					+29.76%
	NOVO NORDISK A/S					+42.83%
	JOHNSON & JOHNSON					+17.01%
	ABBVIE INC.					+18.19%
	ROCHE HOLDING AG					+10.56%
	MERCK & CO., INC.					+30.78%
	ASTRAZENECA PLC					+26.55%
	NOVARTIS AG					+14.12%
	PFIZER, INC.					+19.86%
	Average					+22.57%
	Weighted average by Cap.					+24.59%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

273.44USD

Average target price

317.24USD

Spread / Average Target

+16.02%

High Price Target

405.00USD

Spread / Highest target

+48.11%

Low Price Target

195.00USD

Spread / Lowest Target

-28.69%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Wells Fargo Securities
Goldman Sachs
Truist Securities
RBC Capital Markets
Jefferies & Co.
UBS
Deutsche Bank Securities
Leerink Partners
Redburn Atlantic
Citigroup
HSBC
Morgan Stanley
TD Cowen
JPMorgan Chase
Barclays
Mizuho Securities
William Blair & Co.
BMO Capital
Oppenheimer
Baird
Daiwa Securities
Argus
Credit Suisse
DA Davidson
Piper Sandler
SVB Securities LLC
Cowen
Atlantic Equities
BofA Securities
SVB Leerink
JPMORGAN	Cory Kasimov
RBC	Kennen Mackay